type 2 diabetes
Conditions
Interventions
Continue DPP-4 inhibitors (regular dose) or switch to oral semaglutide.
Participants in the semaglutide group follow an escalation regimen of semaglutide 7mg (maintenance dose reached after 4 weeks o
Sponsors
Ohara Makoto
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a diagnosis of type 2 diabetes mellitus 1) HbA1c 7.0% or more 2) treatment with DPP-4 inhibitors for 12weeks or longer 3) written informed consent 4) 20 years and over
Exclusion criteria
Exclusion criteria: 1)the use of steroids or anti-inflammatory drugs, 2)diabetic ketosis and coma within 3 months before the study, 3)severe infection, severe trauma, pre-and post-operation, 4)an estimated glomerular filtration rate are within 30mL/min/1.73m2, 5)malignancy, 6)pregnancy 7)Patients who are judged as inappropriate for inclusion by phsicians 8)Patients using implantable medical devices such as cardiac pacemakers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point was d-ROMs change from baseline after completing 24 weeks of treatment intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)The change in glucose variability at 24 weeks from baseline 2) Inflammation markers and AGE-related markers 3) Glucose metabolism index, lipid metabolism index, Renal function, liver function 4) Eating Behavior Questionnaire and DTSQ 5) Blood pressure, pulse, weight | — |
Contacts
Public ContactMakoto Ohara
Showa University Hospital
Outcome results
None listed